Managing Gout in Women: Current Perspectives

References

• Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3s):S11–s16. doi:10.1016/j.semarthrit.2020.04.008
   PubMed Web of Science ®Google Scholar
• McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452–460.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Bardin T, Doherty M, et al. Discordant American College of Physicians and international Rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017;13(9):561–568. doi:10.1038/nrrheum.2017.126
   PubMed Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879–895. doi:10.1002/art.41247
   PubMed Web of Science ®Google Scholar
• Kuo C-F, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–667. doi:10.1136/annrheumdis-2013-204463
   PubMed Web of Science ®Google Scholar
• Te Kampe R, Janssen M, van Durme C, et al. Sex differences in the clinical profile among patients with gout: cross-sectional Analyses of an Observational Study. J Rheumatol. 2021;48(2):286–292. doi:10.3899/jrheum.200113
   PubMed Web of Science ®Google Scholar
• Harrold LR, Etzel CJ, Gibofsky A, et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18(1):108. doi:10.1186/s12891-017-1465-9
   PubMed Web of Science ®Google Scholar
• Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69(7):1305–1309. doi:10.1136/ard.2009.109884
   PubMed Web of Science ®Google Scholar
• Roman Y, Tiirikainen M, Prom-Wormley E. The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clin Rheumatol. 2020;39(8):2387–2392. doi:10.1007/s10067-020-04994-9
   PubMed Web of Science ®Google Scholar
• Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;13(2):R39. doi:10.1186/ar3272
   PubMed Web of Science ®Google Scholar
• Narang RK, Topless R, Cadzow M, et al. Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. Arthritis Res Ther. 2019;21(1):13. doi:10.1186/s13075-018-1787-5
   PubMed Web of Science ®Google Scholar
• Yoo H-G, Lee S-I, Chae H-J, et al. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int. 2011;31(4):485–491. doi:10.1007/s00296-009-1304-x
   PubMed Web of Science ®Google Scholar
• Sumpter N, Cadzow M, So A, Reynolds R, Merriman T. Analysis of common gout comorbidities in the UK Biobank cohort reveals sex-specific effects and genetic differentiation. Arthritis Rheumatol. 2020;72:45.
   Web of Science ®Google Scholar
• Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020;50(3s):S24–s30. doi:10.1016/j.semarthrit.2020.04.010
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. doi:10.1136/annrheumdis-2016-209707
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Dalbeth N. Combination urate-lowering therapy in the treatment of gout: what is the evidence? Semin Arthritis Rheum. 2019;48(4):658–668. doi:10.1016/j.semarthrit.2018.06.004
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461. doi:10.1056/NEJMoa050373
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548. doi:10.1002/art.24209
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi:10.1186/ar2978
   PubMed Web of Science ®Google Scholar
• Chohan S, Becker MA, MacDonald PA, et al. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012;64(2):256–261. doi:10.1002/acr.20680
   PubMed Web of Science ®Google Scholar
• Khosravan R, Kukulka MJ, Wu J-T, et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008;48(9):1014–1024. doi:10.1177/0091270008322035
   PubMed Web of Science ®Google Scholar
• Mizuno T, Hayashi T, Hikosaka S, et al. Efficacy and safety of febuxostat in elderly female patients. Clin Interv Aging. 2014;9:1489–1493. doi:10.2147/CIA.S70855
   PubMed Web of Science ®Google Scholar
• Foody J, Turpin RS, Tidwell BA, et al. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. Am Health Drug Benefits. 2017;10(8):393–401.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–1210. doi:10.1056/NEJMoa1710895
   PubMed Web of Science ®Google Scholar
• Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-Based Cohort Study. Circulation. 2018;138(11):1116–1126. doi:10.1161/CIRCULATIONAHA.118.033992
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–1757. doi:10.1016/S0140-6736(20)32234-0
   PubMed Web of Science ®Google Scholar
• Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013;40(6):872–876. doi:10.3899/jrheum.121301
   PubMed Web of Science ®Google Scholar
• Richette P, Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol. 2006;2(6):338–342; quiz 343. doi:10.1038/ncprheum0214
   PubMedGoogle Scholar
• Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant. 2005;20(2):431–433. doi:10.1093/ndt/gfh629
   PubMed Web of Science ®Google Scholar
• Wipfler-Freibmuth E, Dejaco C, Duftner C, et al. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report. Clin Exp Rheumatol. 2009;27(4):658–660.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–720.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Becker MA, Baraf HSB, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a Phase II randomized study. Arthritis Rheum. 2008;58(9):2882–2891. doi:10.1002/art.23810
   PubMed Web of Science ®Google Scholar
• Araujo EG, Bayat S, Petsch C, et al. Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open. 2015;1(1):e000075. doi:10.1136/rmdopen-2015-000075
   PubMed Web of Science ®Google Scholar
• Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004;50(2):598–606. doi:10.1002/art.20007
   PubMed Web of Science ®Google Scholar
• Navarra S, Rubin BR, Yu Q, et al. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Curr Med Res Opin. 2007;23(7):1685–1691. doi:10.1185/030079907X210750
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068. doi:10.1002/art.27327
   PubMed Web of Science ®Google Scholar
• Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–2775. doi:10.1093/eurheartj/ehab115
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. doi:10.1056/NEJMoa2021372
   PubMed Web of Science ®Google Scholar
• Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19(6):329–336. doi:10.1016/0049-0172(90)90070-V
   PubMed Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. doi:10.1186/ar2143
   PubMed Web of Science ®Google Scholar
• Chen K, Fields T, Mancuso CA, et al. Anakinra’s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40(3):210–214. doi:10.1016/j.semarthrit.2010.03.001
   PubMed Web of Science ®Google Scholar
• Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford. 2019;58(8):1344–1352. doi:10.1093/rheumatology/key402
   Web of Science ®Google Scholar
• Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015;45(1):81–85. doi:10.1016/j.semarthrit.2015.02.006
   PubMed Web of Science ®Google Scholar
• Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol. 2019;46(10):1345–1349. doi:10.3899/jrheum.181018
   PubMed Web of Science ®Google Scholar
• Lhotta K, Gehringer A, Jennings P, et al. Familial juvenile hyperuricemic nephropathy: report on a new mutation and a pregnancy. Clin Nephrol. 2009;71(1):80–83. doi:10.5414/CNP71080
   PubMed Web of Science ®Google Scholar
• Simmonds HA, Cameron JS, Goldsmith DJ, et al. Familial juvenile hyperuricaemic nephropathy is not such a rare genetic metabolic purine disease in Britain. Nucleosides Nucleotides Nucleic Acids. 2006;25(9–11):1071–1075. doi:10.1080/15257770600891028
   PubMed Web of Science ®Google Scholar
• van Veen TR, Haeri S. Gout in pregnancy: a case report and review of the literature. Gynecol Obstet Invest. 2015;79(4):217–221. doi:10.1159/000369999
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996;39(7):1213–1217. doi:10.1002/art.1780390721
   PubMed Web of Science ®Google Scholar
• Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–2964. doi:10.1093/eurheartj/ehv318
   PubMed Web of Science ®Google Scholar
• Fazal MW, Doogue MP, Leong RW, et al. Allopurinol use in pregnancy in three women with inflammatory bowel disease: safety and outcomes: a case series. BMC Gastroenterol. 2013;13:172. doi:10.1186/1471-230X-13-172
   PubMed Web of Science ®Google Scholar
• Allopurinol. Drugs and Lactation Database (Lactmed). Bethesda (MD): National Library of Medicine (US); 2006.
   Google Scholar